Αποτελέσματα Αναζήτησης
26 Ιουλ 2024 · This study evaluated the safety and efficacy of 150-ppm intermittent iNO administered with a novel iNO-generator, for treating adults hospitalised for viral pneumonia.
3 Αυγ 2023 · Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic calicheamicin payload via an acid labile linker.
15 Απρ 2018 · Background: Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients.
23 Ιουν 2005 · Inhaled nitric oxide (iNO) has been used for treatment of acute respiratory failure and pulmonary hypertension since 1991 in adult patients in the perioperative setting and in critical care.
25 Αυγ 2016 · Methods: In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group).
5 Νοε 2020 · Conclusion: Replacement of conventional induction chemotherapy by InO is feasible, results in promising remission rates, and may reduce the risk of early morbidity and lethality, particular in older patients with acute B lymphoblastic leukemia.
12 Νοε 2020 · The role of inhaled nitric oxide (iNO) in the management of severe hypoxia due to coronavirus disease 2019 (Covid-19) is a subject of debate. Despite the lack of clinical data, the surviving sepsis campaign recommended the use of iNO as a rescue therapy in such patients with persistent hypoxemia and, at the same time, reminded that this ...
